We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+12.59%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$18.9B
AUM Growth
+$3.55B
(+23%)
Cap. Flow
+$2.11B
Cap. Flow
% of AUM
11.15%
Top 10 Holdings %
Top 10 Hldgs %
14.56%
Holding
1,090
New
199
Increased
468
Reduced
192
Closed
179
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$216M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$129M |
| 3 |
Brown & Brown
BRO
|
+$121M |
| 4 |
Arthur J. Gallagher & Co
AJG
|
+$116M |
| 5 |
AKRO
Akero Therapeutics
AKRO
|
+$90.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$144M |
| 2 |
MetLife
MET
|
+$97.2M |
| 3 |
Travelers Companies
TRV
|
+$91.9M |
| 4 |
Electronic Arts
EA
|
+$91.9M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.08% |
| 2 | Technology | 23.91% |
| 3 | Financials | 10.59% |
| 4 | Consumer Discretionary | 9.42% |
| 5 | Industrials | 7.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
651
Solid Biosciences
SLDB
$854M
| $3.08M | 0.02% |
631,823
| – | – |
|
652
Ventas
VTR
$46.4B
| $3.08M | 0.02% |
48,709
+11,883
| +32% | +$776K |
|
653
ProQR Therapeutics
PRQR
$251M
| $3.07M | 0.02% |
1,504,000
+178,345
| +13% | +$290K |
|
654
Tractor Supply
TSCO
$17.2B
| $3.03M | 0.02% |
57,351
+12,219
| +27% | +$625K |
|
655
Raymond James Financial
RJF
$34.4B
| $3.01M | 0.02% |
19,643
+4,063
| +26% | +$582K |
|
|
SEPN
656
Septerna Inc
SEPN
$1.69B
| $2.99M | 0.02% |
282,585
-300,000
| -51% | -$2.47M |
|
657
DTE Energy
DTE
$29.4B
| $2.97M | 0.02% |
22,447
+4,938
| +28% | +$664K |
|
|
CDTX
658
DELISTED
Cidara Therapeutics
CDTX
| $2.97M | 0.02% |
+61,040
| New | +$1.47M |
|
|
FITB
659
Fifth Third Bancorp
FITB
$52.8B
| $2.97M | 0.02% |
72,202
+15,610
| +28% | +$586K |
|
660
Copart
CPRT
$27B
| $2.97M | 0.02% |
60,501
+35,833
| +145% | +$2.01M |
|
661
Wave Life Sciences
WVE
$1.16B
| $2.94M | 0.02% |
452,060
| – | – |
|
662
American Water Works
AWK
$26.6B
| $2.93M | 0.02% |
21,094
+4,628
| +28% | +$663K |
|
663
Rapid7
RPD
$702M
| $2.91M | 0.02% |
125,641
+38,929
| +45% | +$923K |
|
664
Flowserve
FLS
$10.1B
| $2.9M | 0.02% |
+55,364
| New | +$2.6M |
|
665
Arcutis Biotherapeutics
ARQT
$3.27B
| $2.88M | 0.02% |
205,510
-204,490
| -50% | -$2.87M |
|
666
lululemon athletica
LULU
$13.9B
| $2.84M | 0.02% |
11,957
-8,407
| -41% | -$2.32M |
|
667
Ameren
AEE
$30.3B
| $2.81M | 0.01% |
29,235
+6,433
| +28% | +$625K |
|
668
IQVIA
IQV
$37.6B
| $2.8M | 0.01% |
+17,779
| New | +$2.68M |
|
669
Warner Bros
WBD
$65.5B
| $2.79M | 0.01% |
+243,544
| New | +$2.27M |
|
670
GoDaddy
GDDY
$11.3B
| $2.78M | 0.01% |
+15,413
| New | +$2.77M |
|
671
Tyler Technologies
TYL
$12.7B
| $2.77M | 0.01% |
4,665
+1,049
| +29% | +$594K |
|
672
Synchrony
SYF
$25.7B
| $2.75M | 0.01% |
41,176
+5,594
| +16% | +$313K |
|
673
SBA Communications
SBAC
$19.7B
| $2.73M | 0.01% |
11,623
-315,050
| -96% | -$72.1M |
|
674
Pliant Therapeutics
PLRX
$65.6M
| $2.72M | 0.01% |
2,348,526
-165,558
| -7% | -$234K |
|
675
Dollar General
DG
$28.2B
| $2.72M | 0.01% |
23,792
+5,212
| +28% | +$517K |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q2 2025 Portfolio in Review
As of Q2 2025, Woodline Partners held 1,090 positions worth $18.9B, up 23% from $15.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Woodline Partners deployed $2.11B of net new capital in Q2 2025, opening 199 new positions and adding to 468 existing holdings. Its largest new stake was Brown & Brown: 1,079,076 shares worth $120M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 30% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was SpringWorks Therapeutics, an estimated $76M trimmed.
- Woodline Partners's largest Q2 2025 buy was Brown & Brown: 1,079,076 shares worth $120M.
- Woodline Partners added most to Microsoft in Q2 2025, an estimated $216M increase.
- Woodline Partners's biggest Q2 2025 reduction was SpringWorks Therapeutics, cutting an estimated $76M.
- Woodline Partners fully exited Lam Research in Q2 2025, selling an estimated $144M.
- Woodline Partners's ten largest holdings make up 15% of its $18.9B portfolio in Q2 2025.
- Woodline Partners opened 199 new positions and closed 179 in Q2 2025.
- Woodline Partners's portfolio value rose 23% quarter-over-quarter to $18.9B.
Based on Woodline Partners's 13F filing for Q2 2025, filed 14 Aug 2025.